drug name	side effect	side effect	side effect	side effect	side effect	interacts with
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
cetuximab	somnolence	headache	cough	renal failure	carcinoma	
denileukin diftitox	dizziness	headache	pain	dehydration	vasodilatation	
denileukin diftitox	dizziness	headache	pain	dehydration	vasodilatation	
denileukin diftitox	dizziness	headache	pain	dehydration	vasodilatation	
denileukin diftitox	dizziness	headache	pain	dehydration	vasodilatation	
denileukin diftitox	dizziness	headache	pain	dehydration	vasodilatation	
etanercept	dizziness	abdominal pain	nausea	melanoma		
etanercept	dizziness	abdominal pain	nausea	melanoma		
etanercept	dizziness	abdominal pain	nausea	melanoma		
etanercept	dizziness	abdominal pain	nausea	melanoma		
etanercept	dizziness	abdominal pain	nausea	melanoma		

interacts with	interacts with	disease name	disease category
		Adenocarcinoma	Cancer
		Complementary component deficiency	Immunological
		IgG receptor I, phagocytic, familial deficiency of	Immunological
		Lupus erythematosus	Connective tissue disorder
		Lymphoma	Cancer
		Neutropenia	Hematological
		Nonsmall cell lung cancer	Cancer
		Viral infection	Immunological
		Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 21198	Cancer
		C1q deficiency, type A	Immunological
		C1q deficiency, type B	Immunological
		C1s deficiency, isolated	Immunological
		Lupus nephritis, susceptibility to	Connective tissue disorder
		Lymphoma, progression of	Cancer
		Neutropenia, alloimmune neonatal	Hematological
		Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 2119	Cancer
		Viral infections, recurrent	Immunological
		Interleukin-2 receptor, alpha chain, deficiency of	Immunological
		Severe combined immunodeficiency	Immunological
		Combined immunodeficiency	Immunological
		Combined immunodeficiency, X-linked, moderate, 312863	Immunological
		Severe combined immunodeficiency, X-linked, 300400	Immunological
		Asthma	Respiratory
		Asthma	Respiratory
		Complementary component deficiency	Immunological
		Complementary component deficiency	Immunological
		Dementia	Neurological

drug category	product name	company name
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	ERBITUX	ImClone LLC
Antineoplastic agents	Ontak	Eisai Inc.
Antineoplastic agents	Ontak	Eisai Inc.
Antineoplastic agents	Ontak	Eisai Inc.
Antineoplastic agents	Ontak	Eisai Inc.
Antineoplastic agents	Ontak	Eisai Inc.
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
		,
Antirheumatic agents	ENBREL	Immunex Corporation
	:	

clinical trial title
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

clinical trial start date clinical	trial completion date clinical	trial participants	clinical trial status	clinical trial condition
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01		Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.01.01	2011.06.01	41	Completed	Carcinoma, Non-small-cell Lung
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6	Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48	Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01		Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01		Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01		Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01		Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01		Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01		Active, not recruiting	Graft Versus Host Disease

clinical trial condition	clinical trial address	clinical trial institution	clinical trial address	clinical trial main researcher
Laryngeal Neoplasms Austria		Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms Austria		Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms Austria		Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasm	s Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasm	s Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasm	s Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasm	S Austria	Medical University of Vienna	University Hospital, Internal Medicine	
Laryngeal Neoplasm	S Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasm	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasm	Austria	Medical University of Vienna	University Hospital, Internal Medicine	
Laryngeal Neoplasm	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasm	Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasm	S Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasm	S Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasms Austria		Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Laryngeal Neoplasm	Austria	Medical University of Vienna	University Hospital, Internal Medicine	
Laryngeal Neoplasm	s Austria	Medical University of Vienna	University Hospital, Internal Medicine	Wolfgang Hilbe
Psoriasis	United States	University of Alabama at Birminghan	IAR Dermatology	Boni Elewski, MD
F 50110515				
Descie	United States			John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan	······································	Boni Elewski, MD
	United States		University of Michigan Cancer Center	***************************************
Psoriasis	United States	University of Alabama at Birminghan	·	Boni Elewski, MD
	United States		•	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan	(·····································	Boni Elewski, MD
	United States		University of Michigan Cancer Center	
Psoriasis	United States	University of Alabama at Birminghan	UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente	University of Michigan Cancer Center	John Levine, MD

clinical trial condition				
Mouth Neoplasms				
Melanoma				
Melanoma				
Melanoma				
Melanoma				
Melanoma				

etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	

Dementia	Neurological
IgG receptor I, phagocytic, familial deficiency of	Immunological
IgG receptor I, phagocytic, familial deficiency of	Immunological
Lupus erythematosus	Connective tissue disorder
Lupus erythematosus	Connective tissue disorde
Lymphoma	Cancer
Lymphoma	Cancer
Malaria	Immunological
Malaria	Immunological
Migraine	Neurological
Migraine	Neurological
Myocardial infarction	Cardiovascular
Myocardial infarction	Cardiovascular
Neutropenia	Hematological
Neutropenia	Hematological
Sepsis	Immunological

Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation

Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

2012 04 01	6 Completed	Non-melanoma Skin Cancer
······· i ·····		Graft Versus Host Disease
		Non-melanoma Skin Cancer
······ i ·····		Graft Versus Host Disease
······· · ·····		Non-melanoma Skin Cancer
		Graft Versus Host Disease
		Non-melanoma Skin Cancer
······ i ······		Graft Versus Host Disease
		Non-melanoma Skin Cancer
······ i ·····		Graft Versus Host Disease
······································	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01		Non-melanoma Skin Cancer
2015.09.01		Graft Versus Host Disease
······································		Non-melanoma Skin Cancer
		Graft Versus Host Disease
·······		Non-melanoma Skin Cancer
······		Graft Versus Host Disease
	2015.09.01 2012.04.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01	2015.09.01 48 Active, not recruiting 2012.04.01 6 Completed 2015.09.01 48 Active, not recruiting 2015.09.01 48 Active, not recruiting 2012.04.01 6 Completed 2015.09.01 48 Active, not recruiting 2015.09.01

Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	:	John Levine, MD

Melanoma
Melanoma
Melanoma
Melanoma
Melanoma

etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	

Sepsis	Immunological
Viral infection	Immunological
Viral infection	Immunological
Asthma, susceptibility to, 600807	Respiratory
Asthma, susceptibility to, 600807	Respiratory
C1q deficiency, type A	Immunological
C1q deficiency, type A	Immunological
C1q deficiency, type B	Immunological
C1q deficiency, type B	Immunological
C1s deficiency, isolated	Immunological
C1s deficiency, isolated	Immunological
Dementia, vascular, susceptibility to	Neurological
Dementia, vascular, susceptibility to	Neurological
Lupus nephritis, susceptibility to	Connective tissue disorder
Lupus nephritis, susceptibility to	Connective tissue disorder
Lymphoma, progression of	Cancer

Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation

Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra Can We Miss Pigmented Lesions in Psoriasis Patients?

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

2012 04 01	6 Completed	Non-melanoma Skin Cancer
······· i ·····		Graft Versus Host Disease
		Non-melanoma Skin Cancer
······ i ·····		Graft Versus Host Disease
······· · ·····		Non-melanoma Skin Cancer
		Graft Versus Host Disease
		Non-melanoma Skin Cancer
······ i ······		Graft Versus Host Disease
		Non-melanoma Skin Cancer
······ i ·····		Graft Versus Host Disease
······································	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01	6 Completed	Non-melanoma Skin Cancer
2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2012.04.01		Non-melanoma Skin Cancer
2015.09.01		Graft Versus Host Disease
······································		Non-melanoma Skin Cancer
		Graft Versus Host Disease
·······		Non-melanoma Skin Cancer
······		Graft Versus Host Disease
	2015.09.01 2012.04.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01 2015.09.01	2015.09.01 48 Active, not recruiting 2012.04.01 6 Completed 2015.09.01 48 Active, not recruiting 2015.09.01 48 Active, not recruiting 2012.04.01 6 Completed 2015.09.01 48 Active, not recruiting 2015.09.01

Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	:	John Levine, MD

Melanoma
Melanoma
Melanoma
Melanoma
Melanoma

etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
etanercept	dizziness	abdominal pain	nausea	melanoma	
urokinase	back pain	fever	nausea		
urokinase	back pain	fever	nausea		
urokinase	back pain	fever	nausea		
urokinase	back pain	fever	nausea		
urokinase	back pain	fever	nausea		
urokinase	back pain	fever	nausea		

Lymphoma, progression of	Cancer
Malaria assabust susaastibilituta	
Malaria, cerebral, susceptibility to	Immunological
Malaria, cerebral, susceptibility to	Immunological
Migraine without aura, susceptibility to, 157300	Neurological
Migraine without aura, susceptibility to, 157300	Neurological
Myocardial infarction, susceptibility to	Cardiovascular
Myocardial infarction, susceptibility to	Cardiovascular
Neutropenia, alloimmune neonatal	Hematological
Neutropenia, alloimmune neonatal	Hematological
Septic shock, susceptibility to	Immunological
Septic shock, susceptibility to	Immunological
Viral infections, recurrent	Immunological
Viral infections, recurrent	Immunological
Alzheimer disease	Neurological
Conjunctivitis, ligneous	Ophthamological
Plasminogen deficiency	Hematological
Alzheimer disease, late-onset, susceptibility to, 104300	Neurological
Conjunctivitis, ligneous, 217090	Ophthamological
Plasminogen Tochigi disease	Hematological

Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
A (1)	ENDE	
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agonto	FNDDFI	Immunoy Corporation
Immunomodulatory agents	ENDREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
7 thinneamatic agents		initiality corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Antirheumatic agents	ENBREL	Immunex Corporation
Immunomodulatory agents	ENBREL	Immunex Corporation
Thrombolytic agents	Kinlytic	ImaRx Therapeutics, Inc.
Thrombolytic agents	Kinlytic	ImaRx Therapeutics, Inc.
Thrombolytic agents	Kinlytic	ImaRx Therapeutics, Inc.
Thrombolytic agents	Kinlytic	ImaRx Therapeutics, Inc.
Thrombolytic agents	Kinlytic	ImaRx Therapeutics, Inc.
Thrombolytic agents	Kinlytic	ImaRx Therapeutics, Inc.

Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra
Can We Miss Pigmented Lesions in Psoriasis Patients?
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Tra

2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
2007.09.01	2012.04.01	6 Completed	Non-melanoma Skin Cancer
2009.03.01	2015.09.01	48 Active, not recruiting	Graft Versus Host Disease
		-	

Psoriasis	United States	University of Alabama at Birmingham UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	· · · · · · · · · · · · · · · · · · ·	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Center University of Michigan Cancer Center	John Levine, MD
Psoriasis	United States	University of Alabama at Birminghan UAB Dermatology	Boni Elewski, MD
	United States	University of Michigan Cancer Cente University of Michigan Cancer Center	John Levine, MD

Melanoma
Melanoma
Melanoma
NA I
Melanoma
Melanoma
Melanoma
 Melanoma
Melanoma
Melanoma
Weldriema
Melanoma
Melanoma
Melanoma
Melanoma

abciximab			
abciximab			
hydrocortisone			butabarbital

		Complementary component deficiency	Immunological
		Complementary component deficiency	Immunological
		Glanzmann thrombasthenia	Hematological
		Glanzmann thrombasthenia	Hematological
		lgG receptor I, phagocytic, familial deficiency of	Immunological
		IgG receptor I, phagocytic, familial deficiency of	Immunological
		Lupus erythematosus	Connective tissue disorder
		Lupus erythematosus	Connective tissue disorder
		Lymphoma	Cancer
		Lymphoma	Cancer
		Neutropenia	Hematological
		Neutropenia	Hematological
		Viral infection	Immunological
		Viral infection	Immunological
		C1q deficiency, type A	Immunological
		C1q deficiency, type A	Immunological
		C1q deficiency, type B	Immunological
		C1q deficiency, type B	Immunological
		C1s deficiency, isolated	Immunological
		C1s deficiency, isolated	Immunological
		Glanzmann thrombasthenia, type B	Hematological
		Glanzmann thrombasthenia, type B	Hematological
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, dimished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory

Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anticoagulants	REOPRO	Eli Lilly and Company
Antiplatelet agents	REOPRO	Eli Lilly and Company
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	MyOxin	GM Pharamceuticals, Inc
Anti-inflammatory agents	Trioxin	Vertical Pharmaceuticals, Inc

Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu

2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2006.04.01	2008.12.01	110	Completed	Myocardial Infarction
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral

	Italy	University of Pisa	Cardiothoracic Department, Ospedale	Drof Anna Sonia Detronia
		University of Pisa	Cardiothoracic Department, Ospedale (
	Italy		&	
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	
	Italy	·	Cardiothoracic Department, Ospedale	,
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	Prof. Anna Sonia Petronio
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	Prof. Anna Sonia Petronio
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	Prof. Anna Sonia Petronio
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	Prof. Anna Sonia Petronio
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	Prof. Anna Sonia Petronio
	Italy	University of Pisa	Cardiothoracic Department, Ospedale (Prof. Anna Sonia Petronio
	Italy	University of Pisa	Cardiothoracic Department, Ospedale (Prof. Anna Sonia Petronio
	Italy	University of Pisa	Cardiothoracic Department, Ospedale (Prof. Anna Sonia Petronio
	Italy	University of Pisa	Cardiothoracic Department, Ospedale (Prof. Anna Sonia Petronio
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	Prof. Anna Sonia Petronio
	Italy	University of Pisa	Cardiothoracic Department, Ospedale (***************************************
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	Prof. Anna Sonia Petronio
	Italy	University of Pisa	Cardiothoracic Department, Ospedale (
	Italy	University of Pisa	Cardiothoracic Department, Ospedale	
Influenza in Humans	France	University of Versailles	-	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans		University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans		University of Versailles	§·····	Djillali Annane
Influenza in Humans		University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans		University of Versailles	♦	Djillali Annane
Influenza in Humans		University of Versailles	\$i	Djillali Annane

•••••	
•••••	
•••••	
	I
•••••	
•••••	

hydrocortisone		butabarbital
hydrocortisone		butabarbital

salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, dimished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, dimished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, dimished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, dimished response to antileukotriene treatment in, 600807	Respiratory

A 41 1 51 4 4	i	i
Anti-inflammatory agents	Trioxin	Vertical Pharmaceuticals, Inc
Anti-inflammatory agents	Trioxin	Vertical Pharmaceuticals, Inc
Anti-inflammatory agents	Trioxin	Vertical Pharmaceuticals, Inc
Anti-inflammatory agents	Trioxin	Vertical Pharmaceuticals, Inc
Anti-inflammatory agents	Trioxin	Vertical Pharmaceuticals, Inc
Anti-inflammatory agents	Trioxin	Vertical Pharmaceuticals, Inc
Anti-inflammatory agents	Trioxin	Vertical Pharmaceuticals, Inc
Anti-inflammatory agents	Trioxin	Vertical Pharmaceuticals, Inc
Anti-inflammatory agents	Cipro	Physicians Total Care, Inc.
Anti-inflammatory agents	Cipro	Physicians Total Care, Inc.
Anti-inflammatory agents	Cipro	Physicians Total Care, Inc.
Anti-inflammatory agents	Cipro	Physicians Total Care, Inc.
Anti-inflammatory agents	Cipro	Physicians Total Care, Inc.
Anti-inflammatory agents	Cipro	Physicians Total Care, Inc.
Anti-inflammatory agents	Cipro	Physicians Total Care, Inc.
Anti-inflammatory agents	Cipro	Physicians Total Care, Inc.
Anti-inflammatory agents	Cipro	Physicians Total Care, Inc.
Anti-inflammatory agents	CIPRO	Alcon Laboratories, Inc.
Anti-inflammatory agents	CIPRO	Alcon Laboratories, Inc.
Anti-inflammatory agents	CIPRO	Alcon Laboratories, Inc.
Anti-inflammatory agents	CIPRO	Alcon Laboratories, Inc.
Anti-inflammatory agents	CIPRO	Alcon Laboratories, Inc.
Anti-inflammatory agents	CIPRO	Alcon Laboratories, Inc.
Anti-inflammatory agents	CIPRO	Alcon Laboratories, Inc.
Anti-inflammatory agents	CIPRO	Alcon Laboratories, Inc.
Anti-inflammatory agents	CIPRO	Alcon Laboratories, Inc.
Anti-inflammatory agents	Cipro HC	Stat Rx USA
Anti-inflammatory agents	Cipro HC	Stat Rx USA
Anti-inflammatory agents	Cipro HC	Stat Rx USA
Anti-inflammatory agents	Cipro HC	Stat Rx USA
Anti-inflammatory agents	Cipro HC	Stat Rx USA
Anti-inflammatory agents	Cipro HC	Stat Rx USA

Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu

2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral

Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane

	1
	- 1
	- 1
	- 1
	- 1
	- 1
	1
	1
	-
•••••	•••
	1
	1
	- 1
	- 1
	- 1
	- 1
	1
	[
	- 1
	-
	-
	-
	1
	- 1
	•••
	1
	1
	1
	-
	1
	1
	-
•	•••
	1
	- 1

hydrocortisone			butabarbital
hydrocortisone			butabarbital
hydrocortisone		į	butabarbital
hydrocortisone			butabarbital

salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, dimished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, dimished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, dimished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular

T	•	
Anti-inflammatory agents	Cipro HC	Stat Rx USA
Anti-inflammatory agents	Cipro HC	Stat Rx USA
Anti-inflammatory agents	Cipro HC	Stat Rx USA
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Dukes Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	FIRST Marys Mouthwash Compounding	CutisPharma, Inc.
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Hydrocortisone	A-S Medication Solutions LLC
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium

Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu

2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40 Terminated	Pneumonia, Viral

Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane

	7
•••••	
•••••	
•••••	
•••••	
	- 1

hydrocortisone		butabarbital
hydrocortisone		butabarbital

salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, dimished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, dimished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory
salsalate	midodrine	Atherosclerosis	Cardiovascular
salsalate	midodrine	Cortisol resistance	Endocrine
salsalate	midodrine	Malaria	Immunological
salsalate	midodrine	Obesity	Nutritional
salsalate	midodrine	Asthma, dimished response to antileukotriene treatment in, 600807	Respiratory
salsalate	midodrine	Atherosclerosis, susceptibility to	Cardiovascular
salsalate	midodrine	Malaria, resistance to, 248310	Immunological
salsalate	midodrine	Obesity, adrenal insufficiency, and red hair	Nutritional
salsalate	midodrine	Asthma	Respiratory

Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Premier Value	Chain Drug Consortium
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Cortizone 10 Poison Ivy Relief Pads	Chattem, Inc.
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Family Wellness Hydrocortisone	Family Dollar Services Inc
Anti-inflammatory agents	Pramosone E	Ferndale Laboratories, Inc.

Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu

2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01		Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01		Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01		Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral
2010.03.01	2011.12.01	40	Terminated	Pneumonia, Viral

Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans		University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane
Influenza in Humans	France	University of Versailles	Raymond Poincaré hospital	Djillali Annane